Myeloma: 2016 Year in Review and Outlook for 2017 with Dr. Ravi Vij

1:00:00
 
Share
 

Manage episode 171357089 series 1143960
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose therapy and autologous stem cell transplantation continue to remain a backbone of upfront treatment in myeloma. We are talking to Dr. Ravi Vij, about the evolution of myeloma treatments in the past year and what we can look forward to in the new year. Dr. Ravi Vij is Professor of Medicine, Washington University School of Medicine, St. Louis, MO, Dr. Ravi Vij, serves in the Section of Bone Marrow Transplantation and Leukemia, Division of Oncology. Dr. Vij research focus is the treatment of hematologic malignancies and hematopoietic stem cell transplantation. RSVP Here!

158 episodes available. A new episode about every 20 days averaging 61 mins duration .